🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dr Gabriel Hortobagyi, recipient of the ESMO Breast Award, gives an overview of the development of treatments for ER+ breast cancer #ESMOBreast25

The #TolAlgorithm for treating HR+/HER2- MBC in (the first half of) 2025 Sara Tolaney #ESMOBreast25 #esmoambassadors

Congratulations to my friend and MD Anderson Cancer Center co-fellow Inimfon Jackson on her award, LBJ 2nd year fellow of the year! So well deserved! 🤩✨👏🏼

Huge congratulations to our incredible mentor, Dr. Mariana Chavez MacGregor, on being named MD Anderson Cancer Center Mentor of the Year! I’m greatly appreciative of your guidance, unwavering support and sponsorship. So well deserved! ✨

Congratulations to this year’s class of Conquer Cancer grant and award recipients! Are you one of them? Tell us in the comments! We can't wait to celebrate with you at #ASCO25. Full list of recipients: brnw.ch/21wSR0A ASCO

One week to #ASCO25. Which will be an unprecedented ASCO for breast oncologists. Treatment algorithms will change for ALL disease subtypes. ADCs will climb to earlier lines of treatment. Paradigms will be challenged. Here’s my list of top 10 abstracts. See you in Chicago! #bcsm

ASCENT-03: SG superior to TPC chemo in 1L TNBC (PDL1- or IO ineligible) businesswire.com/news/home/2025…

Outstanding MedPage Today interview w Anne May : A 9m supervised #exercise program for m #BreastCancer not only improves fatigue QoL & side effects — it’s also cost-effective. #ExerciseOncology #ASCO25

Congratulations Jasmine Sukumar MD MD Anderson Cancer Center #ASCO25

In patients with PIK3CA-mutated advanced breast cancer, inavolisib added to palbociclib–fulvestrant led to a significant overall survival benefit, with a higher incidence of certain toxic effects than placebo. Full INAVO120 trial results: nej.md/3Zje7Vt #ASCO25 | ASCO

VERITAC-2 published in NEJM Vepdegestrant ⬆️ mPFS from 2 to 5m but only in ESR1mut. No benefit at all in ESR1 wt nejm.org/doi/full/10.10…

At #ASCO25 Oral Metastatic #breastcancer session Analysis of hyperglycemia in pre-diabetic/obese pts in a phase 1 trial testing inavolisib in PIK3CAmut HR+/HER2-neg mBC Hyperglycemia was frequent in this population (81% anyG, 35% G3-4) Median time to onset 14 days OncoAlert

ASCENT04 changes practice w/ improved mPFS 11.2 vs. 7.8 mos; 12 mon PFS 48 vs 33 mos w/ impressive tail suggesting potential for group with durable sustained response; adverse events were not additive. Bonus points for cross over design. #ASCO25 Sara Tolaney OncoAlert

The NEJM has published SERENA-6 data ahead of ASCO #ASCO25 plenary. Cami joins other SERDS (elacestrant, imlunestrant, vepdegestrant) with activity in ESR1mut BC Key questions to think about ahead of session: nejm.org/doi/full/10.10…

Come on #ASCO25, this 💯 should have been a plenary! 7% improvement in 8-yr OS w exercise in adjuvant colon ca, greater than benefit for adding oxali to 5-FU (5% at 10 yrs in MOSAIC). Exercise = $ effective, ~0 tox, & gives pts sense of empowerment. Congrats Chris Booth et al!

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

Dr Erica Mayer Erica Mayer presents results of the TRADE study - dose escalation of adjuvant abemaciclib from 50 mg bid to 150 mg bid over the first 12 wks reduced drug discontinuation rates and allowed most pts to reach the target dose.

Inspirational words on positioning yourself for success by these four women physician leaders! Sharing experiences in their careers and advice with early career women in oncology. Now we have the tools for success🛠️✨#ASCO2025 Maryam Lustberg MD, MPH, FASCO Yale Cancer Center YaleBreastCancer

Presented at #ASCO25: In the OASIS-4 phase 3 trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor symptoms. Full trial results:

How exercise works through the gut microbiome to enhance response to cancer immunotherapy cell.com/cell/fulltext/… Cell